Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBU-TAB vs IBU-TAB 200
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction,Gouty arthritis (off-label),Patent ductus arteriosus closure in neonates (off-label)
Pain,Fever,Inflammation,Dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Migraine
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Primarily hepatic via CYP2C9; also undergoes glucuronidation. Metabolites include hydroxy- and carboxy-ibuprofen, which are inactive.
Hepatic metabolism primarily via CYP2C9.
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Approximately 99% bound to albumin.
99% bound to albumin.
0.1-0.3 L/kg. The low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid.
0.1-0.2 L/kg (low Vd, confined to plasma and interstitial fluid).
Oral: 80-100% (well absorbed). Topical: approximately 5-10% systemically absorbed (varies with formulation and application site).
Oral: 80-100% (with food may reduce rate).
Cr Cl 30-60 m L/min: reduce dose by 50% and avoid in Cr Cl <30 m L/min.
e GFR 30-59 m L/min: reduce dose by 50% or increase interval to every 8-12 hours; e GFR <30 m L/min: avoid use or maximum 400 mg/day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. For fever or pain: 5 mg/kg per dose for temperatures <102.5°F, 10 mg/kg per dose for higher fever.
Initiate at lowest effective dose (e.g., 200 mg every 8-12 hours); monitor renal function and avoid long-term use.
Start at lowest effective dose (200 mg every 6-8 hours); maximum 400 mg/day due to increased risk of renal and GI adverse effects.
NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk.
Risk of serious GI adverse events including bleeding, ulceration, and perforation; NSAIDs should be used with caution in patients with history of peptic ulcer disease or GI bleeding. May cause renal toxicity, especially in patients with pre-existing renal impairment. Use with caution in patients with asthma, congestive heart failure, or hypertension.
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, hepatic effects, asthma exacerbation, pregnancy avoidance (third trimester).
History of hypersensitivity to ibuprofen or any other NSAID; active peptic ulcer disease or GI bleeding; severe renal impairment; history of serious cardiovascular event; perioperative pain in CABG surgery; third trimester of pregnancy.
Hypersensitivity to ibuprofen or NSAIDs, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of coronary artery bypass graft (CABG) surgery, severe renal impairment, active peptic ulcer disease.
Alcohol may increase risk of GI bleeding. Food delays absorption but does not significantly affect total exposure; take with food to improve tolerability.
Avoid alcohol. Take with food or milk to minimize gastric irritation. Grapefruit juice may modestly increase ibuprofen absorption but clinical significance is low; no strict restriction. Administer with a full glass of water.
First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment; avoid after 30 weeks gestation. Use not recommended during pregnancy.
First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; no clear teratogenic risk but may cause premature closure of ductus arteriosus. Third trimester: Contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment.
Excreted in breast milk in low concentrations (M/P ratio <0.02). American Academy of Pediatrics considers compatible with breastfeeding. Monitor infant for gastrointestinal distress or rash. Use lowest effective dose for shortest duration.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. Monitor infant for rash, gastrointestinal effects, or drowsiness.
Increased clearance and volume of distribution in pregnancy (especially third trimester) may require dose escalation to maintain efficacy. However, due to fetal risks, avoid use; if necessary, use minimal effective dose for shortest duration.
No specific dose adjustment recommended for pregnancy-related pharmacokinetic changes. However, due to increased plasma volume and renal clearance, therapeutic efficacy may be reduced; use lowest effective dose. Avoid in third trimester.
IBU-TAB (ibuprofen) is a non-selective COX inhibitor; use lowest effective dose for shortest duration to minimize GI and renal risks. Avoid in patients with NSAID-sensitive asthma, severe renal impairment (e GFR <30 m L/min), or perioperative pain in CABG surgery. Concomitant aspirin antagonizes irreversible antiplatelet effect; separate by 2 hours if immediate-release. Monitor for fluid retention and hypertension in cardiac patients.
Ibuprofen (IBU-TAB 200) is an NSAID; avoid in patients with Cr Cl <30 m L/min. Dose adjustment not needed for mild hepatic impairment but contraindicated in severe hepatic disease. Use lowest effective dose for shortest duration to minimize renal and GI risk. Can mask signs of infection; monitor for fever in at-risk patients. Not recommended in late pregnancy (after 30 weeks) due to risk of premature ductus arteriosus closure.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg/day without physician approval; higher doses increase risk of bleeding and kidney damage.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Discontinue and seek medical help if you experience signs of allergic reaction (rash, swelling, difficulty breathing) or black/tarry stools.,Inform your doctor about all medications you take, especially blood thinners, aspirin, other NSAIDs, and medications for blood pressure or kidney disease.
Take with food or milk to reduce gastrointestinal upset.,Do not exceed 1200 mg per day without consulting your doctor.,Avoid drinking alcohol while taking this medication as it increases the risk of stomach bleeding.,If you have high blood pressure, heart disease, or kidney disease, use only under medical supervision.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of allergic reaction (rash, swelling, difficulty breathing).,Do not take with other NSAIDs (e.g., aspirin, naproxen) unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBU-TAB vs IBU-TAB 200, answered by our medical review team.
IBU-TAB is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.. IBU-TAB 200 is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBU-TAB and IBU-TAB 200 depend on the specific clinical indication. These are both Nonsteroidal Anti-inflammatory Drug (NSAID) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBU-TAB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of IBU-TAB 200 is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBU-TAB and IBU-TAB 200 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBU-TAB is classified as Category C. First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, ol. IBU-TAB 200 is classified as Category C. First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.